This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
31 Oct 2011

CMC Biologics & Daiichi Sankyo Ink Antibody Pact

CMC Biologics has entered a three-year agreement with Daiichi Sankyo to provide process development support and manufacture of several clinical-stage antibodies.

Denmark's CMC Biologics has signed an agreement with Daiichi Sankyo Co., Ltd. to provide process development support and manufacture of several clinical-stage antibodies for a three-year period.

 

The two companies began work on their first joint project at CMC Biologics' Bothell manufacturing facility.

 

Gustavo F. Mahler, Ph.D., global chief operations officer at CMC Biologics, said,"We will be working closely with Daiichi Sankyo on the development and production of antibodies over the next several years."

 

Junichi Koga, Ph.D., vice president, Biopharmaceutical Technology Research Laboratories at Daiichi Sankyo, said, "

Related News